It has been shown that DDR genes and proteins are more highly expressed and activated in SCLC as compared to NSCLC and that blocking these DDR pathways has antitumoral activity in both preclinical [210] and clinical [211] studies, including many different types of cancer. Here, DDR1 is linked to small cell lung carcinoma.